Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

M Labrie, JS Brugge, GB Mills… - Nature reviews Cancer, 2022 - nature.com
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

IL-6 in inflammation, autoimmunity and cancer

T Hirano - International immunology, 2021 - academic.oup.com
IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone
metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely …

Targeting STAT3 in cancer immunotherapy

S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside

DY Lizardo, C Kuang, S Hao, J Yu, Y Huang… - Biochimica et Biophysica …, 2020 - Elsevier
Colorectal cancers (CRCs) with deficient mismatch repair (dMMR) or microsatellite instability-
high (MSI-H) often have sustained responses to immune checkpoint inhibitors (ICIs) …

The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy

M Garg, MK Shanmugam, V Bhardwaj… - Medicinal research …, 2021 - Wiley Online Library
Signal transducer and activator of transcription 3 (STAT3) is one of the crucial transcription
factors, responsible for regulating cellular proliferation, cellular differentiation, migration …

Microalgae with immunomodulatory activities

G Riccio, C Lauritano - Marine drugs, 2019 - mdpi.com
Microalgae are photosynthetic microorganisms adapted to live in very different environments
and showing an enormous biochemical and genetic diversity, thus representing an excellent …

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B Besse, E Pons-Tostivint, K Park, S Hartl, PM Forde… - Nature medicine, 2024 - nature.com
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …

[HTML][HTML] Novel activators and small-molecule inhibitors of STAT3 in cancer

L Yang, S Lin, L Xu, J Lin, C Zhao, X Huang - Cytokine & Growth Factor …, 2019 - Elsevier
Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is
observed in a subset of many cancers, making activated STAT3 a highly promising potential …

Targeting STAT3 signaling pathway in colorectal cancer

AN Gargalionis, KA Papavassiliou, AG Papavassiliou - Biomedicines, 2021 - mdpi.com
Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor that
has been firmly associated with colorectal cancer (CRC) initiation and development. STAT3 …

Pivotal role of STAT3 in shaping glioblastoma immune microenvironment

C Piperi, KA Papavassiliou, AG Papavassiliou - Cells, 2019 - mdpi.com
Glioblastoma belongs to the most malignant intracranial tumors characterized by
indispensable growth and aggressiveness that highly associates with dismal prognosis and …